Article
Pharmacogenetic-guided dosing for fluoropyrimidine (DPYD) and irinotecan (UGT1A1*28) chemotherapies for patients with cancer (PACIFIC-PGx): A multicenter clinical trial.
Clinical and translational science - 1 Dec 2024
Glewis Sarah, Lingaratnam Senthil, Lee Benjamin, Campbell Ian, IJzerman Maarten, Fagery Mussab, Harris Sam, Georgiou Chloe, Underhill Craig, Warren Mark, Campbell Robert, Jayawardana Madawa, Silva S Sandun M, Martin Jennifer H, Tie Jeanne, Alexander Marliese, Michael Michael
Abstract excerpt
PACIFIC-PGx evaluated the feasibility of implementing pharmacogenetics (PGx) screening in Australia and the impact of DPYD/UGT1A1 genotype-guided dosing on severe fluoropyrimidine (FP) and irinotecan-related toxicities and hospitalizations, compared to historical controls. This prospective single arm trial enrolled patients starting FP/irinotecan for any cancer between 7 January 2021 and 25 February 2022 from...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.